Following James Lim’s last BDX Sell transaction on September 11, 2017, the stock climbed by 35.6%. In addition to James Lim, one other BDX executive reported Sell trades in the last month.
Based on Becton Dickinson’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $4.4 billion and GAAP net loss of $135 million. In comparison, last year the company earned revenue of $3.17 billion and had a net profit of $327 million. BDX’s market cap is $63.38B and the company has a P/E ratio of 538.32. Currently, Becton Dickinson has an average volume of 874.9K.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $274.00, reflecting a 15.7% upside.
The insider sentiment on Becton Dickinson has been negative according to 69 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.